Scholarlink

Background <p>For stage IVB gastric cancer, recently, systemic cancer therapy (including cytotoxic chemotherapy, immune checkpoint inhibitors, and molecular targeted agents) is the standard treatment based on biomarker testing. If these treatments are successful and the tumor becomes resectable, conversion surgery may be considered, though its significance remains unclear. In cases showing clinical complete response (cCR), the necessity of surgery is further debated.</p> Methods <p>This retrospective single-center study included patients with cStage IVB gastric cancer who received chemotherapy or systemic cancer therapy, regardless of undergoing conversion surgery, between 2013 and 2023. Patients were stratified by objective tumor response on imaging (cCR or others). Those achieving cCR were further divided into two groups: non-OP (follow-up without surgery) and OP (underwent conversion surgery) for survival comparison.</p> Results <p>Among 1591 patients treated with systemic chemotherapy, 51 (3.2%) achieved cCR (33 non-OP; 18 OP). In the cCR cohort, the median follow-up was 57 months. The 3-year overall survival (OS) was 97% in the non-OP group and 86% in the OP group (<i>P</i> = 0.44), respectively. Among the entire population, conversion surgery was performed in 121 patients (7.6%), in whom pathological CR (pCR) was seen in 17 (14%). This included 10 patients with cCR and seven without cCR. Three-year OS of pCR patients was 93%.</p> Conclusions <p>The results suggested the potential for long-term survival without surgery in patients showing cCR. However, further investigation is needed regarding accurate methods to assess tumor disappearance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy?

  • 期刊论文

  • 发表日期：

    2025年10月30日

查看全文
  • Takumi Habu,
  • Shinpei Ushiyama,
  • Izuma Nakayama,
  • Masahiro Yura,
  • Mitsumasa Yoshida,
  • Naoya Sakamoto,
  • Takeshi Kuwata,
  • Kohei Shitara,
  • Takahiro Kinoshita

摘要

Background

For stage IVB gastric cancer, recently, systemic cancer therapy (including cytotoxic chemotherapy, immune checkpoint inhibitors, and molecular targeted agents) is the standard treatment based on biomarker testing. If these treatments are successful and the tumor becomes resectable, conversion surgery may be considered, though its significance remains unclear. In cases showing clinical complete response (cCR), the necessity of surgery is further debated.

Methods

This retrospective single-center study included patients with cStage IVB gastric cancer who received chemotherapy or systemic cancer therapy, regardless of undergoing conversion surgery, between 2013 and 2023. Patients were stratified by objective tumor response on imaging (cCR or others). Those achieving cCR were further divided into two groups: non-OP (follow-up without surgery) and OP (underwent conversion surgery) for survival comparison.

Results

Among 1591 patients treated with systemic chemotherapy, 51 (3.2%) achieved cCR (33 non-OP; 18 OP). In the cCR cohort, the median follow-up was 57 months. The 3-year overall survival (OS) was 97% in the non-OP group and 86% in the OP group (P = 0.44), respectively. Among the entire population, conversion surgery was performed in 121 patients (7.6%), in whom pathological CR (pCR) was seen in 17 (14%). This included 10 patients with cCR and seven without cCR. Three-year OS of pCR patients was 93%.

Conclusions

The results suggested the potential for long-term survival without surgery in patients showing cCR. However, further investigation is needed regarding accurate methods to assess tumor disappearance.